XClose

Psychiatry

Home
Menu

Research News and Progress

Publications

Hearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol [version 2; peer review: 2 approved, 1 approved with reservations]. Murtough S, Panconesi D, Lu C. et al. Wellcome Open Res. 2024;9:546. doi:10.12688/wellcomeopenres.23013.2
A systematic review of pharmacogenetic testing to guide antipsychotic treatment. Saadullah Khani N, Hudson G, Mills G, et al. Nat Ment Health. 2024;2(5):616-626. doi:10.1038/s44220-024-00240-2

Psychosis Endophenotypes: A Gene-Set-Specific Polygenic Risk Score Analysis. Wang B, Irizar H, Thygesen JH, et al. Schizophr Bull. 2023;49(6):1625-1636. doi:10.1093/schbul/sbad088

Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19CYP2D6 genes play a role? A UK population-based study. Richards-Belle A, Austin-Zimmerman I, Wang B, et al. J Psychopharmacol. 2023;37(4):396-407. doi:10.1177/02698811231152748

The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Austin-Zimmerman I, Wronska M, Wang B, et al. Genes (Basel). 2021;12(11):1758. doi:10.3390/genes12111758

Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study. Thygesen JH, Presman A, Harju-Seppänen J, et al. Mol Psychiatry. 2021;26(9):5307-5319. doi:10.1038/s41380-020-0820-7

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis. Calafato MS, Austin-Zimmerman I, Thygesen JH, et al. Pharmacogenomics J. 2020;20(5):629-637. doi:10.1038/s41397-019-0142-9

Conference Attendence

World Congress of Psychiatric Genetics 2024 (Singapore)

Implementing ACKR1 variant testing in England for clozapine therapy. Murtough S, Mills D, Abidoph R, et al. Euro Neuro. 2024. doi:10.1016/j.euroneuro.2024.08.492

Adaptive-sampling nanopore sequencing in the G-PAT study: A multi-omics approach for the characterisation of rare pharmacogene variants in psychosis. Cotic M, Saadullah Khani N, Varney L, et al. Euro Neuro. 2024. doi:10.1016/j.euroneuro.2024.08.488

Cost-effectiveness analysis of pharmacogenetic testing to guide treatment in schizophrenia. Saadullah Khani N, Murtough S, Richards-Belle A, et al. Euro Neuro. 2024. doi:10.1016/j.euroneuro.2024.08.500

World Congress of Psychiatric Genetics 2023 (Canada)

Assessment of pharmacogenetic analysis technologies applied in the G-PAT study: Multi-modal characterisation of key pharmacogenes in the context of psychosis. Cotic M, Saadullah Khani N, Varney L, et al. Euro Neuro. 2023. doi:10.1016/j.euroneuro.2023.08.273

Polygenic scores and the relationship between cognition and psychosisVarney L, Wang B, Cotic M, et al. Euro Neuro. 2023. doi:10.1016/j.euroneuro.2023.08.378

Pharmacogenetic testing to guide antipyschotic treatment: A systematic review and meta-analysis. Saadullah Khani N, Hudson G, Mills G, et al. Euro Neuro. 2023. doi:10.1016/j.euroneuro.2023.08.373


Other ongoing studies

The research team are also working on another study, Biomarkers for Psychosis and their Genetic Importance, which can be found here.